Post Marketing Surveillance Study To Observe Safety And Efficacy Of Aromasin In The Patients With Early Or Advanced Breast Cancer

CompletedOBSERVATIONAL
Enrollment

206

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions
Breast Cancer
Interventions
DRUG

Aromasin

25 mg table QD

DRUG

Aromasin

25 mg table QD

Trial Locations (22)

330-721

Soon Chun Hyang University Hospital Cheonan, Cheonan

431-070

Hallym University Sacred Heart Hospital, Anyang-si

420-767

Soon Chun Hyang University Bucheon Hospital, Bucheon-si

412-270

Myongji Hospital, Kwangdong Unversity College of Medicine, Goyang-si

570-749

Wonkwang University School of Medicine and Hospital (WUH), Iksan -si

138-736

Asan Medical Center, Seoul

Asan Medical Center, University of Ulsan, Seoul

110-744

Seoul National University Hospital (SNUH), Seoul

Seoul National University Hospital, Seoul

519-809

Hwasun Hospital, Chonnam National University, Cheonnam

614-735

Inje University Busan Paik Hospital, Busan

705-717

Yeung Nam University Hospital, Daegu

463-707

Seoul National University Bundang Hospital, Gyeonggi-do

400-711

Inha University Hospital, Incheon

100-380

Cheil General Hospital & Women's Healthcare Center, Seoul

120-752

Severance Hospital, Yonsei University Health System, Yonsei Cancer Center, Seoul

135 710

Samsung Medical Center, Seoul

136-705

Korea University Anam Hospital, Seoul

152-703

Korea University Medical Center (KUMC) - Korea University Guro Hospital, Seoul

156-707

SMG-SNU Boramae Medical Center, Seoul

158-710

Ewha Womans University Mokdong Hospital, Seoul

443-380

Ajou University Hospital, Suwon

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01047358 - Post Marketing Surveillance Study To Observe Safety And Efficacy Of Aromasin In The Patients With Early Or Advanced Breast Cancer | Biotech Hunter | Biotech Hunter